Markets:

Overview

News

Currencies

International

Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

6.810 +0.140 (+2.10%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

A Glimpse Into The Expert Outlook On Taysha Gene Therapies Through 11 Analysts ↗

August 13, 2025

Via Benzinga

What's Next: Taysha Gene Therapies's Earnings Preview ↗

August 11, 2025

Via Benzinga

Beyond The Numbers: 10 Analysts Discuss Taysha Gene Therapies Stock ↗

July 01, 2025

Via Benzinga

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data ↗

June 03, 2025

Canaccord Genuity raised its price target on Taysha Gene Therapies to $11 from $9, citing improved clinical data and increased confidence in the company’s TSHA-102 program.

Via Stocktwits

Where Taysha Gene Therapies Stands With Analysts ↗

June 02, 2025

Via Benzinga

Why Is Taysha Gene Therapies Stock Trading Higher On Thursday? ↗

May 29, 2025

Taysha shared the TSHA-102 trial plan after FDA alignment and reported 100% milestone gains with no serious adverse events in Rett syndrome patients.

Via Benzinga

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Assessing Taysha Gene Therapies: Insights From 8 Financial Analysts ↗

January 06, 2025

Via Benzinga

Expert Outlook: Taysha Gene Therapies Through The Eyes Of 7 Analysts ↗

November 15, 2024

Via Benzinga

Earnings Scheduled For November 13, 2024 ↗

November 13, 2024

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 29, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 28, 2025

Via Benzinga

Get insights into the top gainers and losers of Wednesday's after-hours session. ↗

May 28, 2025

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

Expert Outlook: Taysha Gene Therapies Through The Eyes Of 6 Analysts ↗

May 16, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

May 15, 2025

Via Benzinga

Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗

May 07, 2025

FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.

Via Benzinga

Top stock movements in today's session. ↗

March 31, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

Earnings Scheduled For May 15, 2025 ↗

May 15, 2025

Via Benzinga

Monday's session: top gainers and losers ↗

March 31, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 31, 2025

Via Benzinga

These stocks are gapping in today's session ↗

March 31, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet ↗

March 31, 2025

Via Benzinga

Topics Stocks

Hillenbrand Posts Better-Than-Expected Earnings, Joins Beazer Homes, Tapestry, Walt Disney And Other Big Stocks Moving Higher On Thursday ↗

November 14, 2024

Via Benzinga

Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

November 14, 2024

Via Benzinga

Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"

November 14, 2024

Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.

Via MarketBeat

Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket ↗

November 14, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 12, 2024

Via Benzinga

Dow Dips Over 200 Points; Home Depot Posts Upbeat Earnings ↗

November 12, 2024

Via Benzinga

Topics Stocks

Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday ↗

November 12, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.